Applied Immune Technologies tcrl.co.il


Public list: Pharma Startups (6570) Portfolio Company Matchmaking M&A (394) Cancer Therapeutics (1180)

Applied Immune Technologies (AIT) is a drug development company specializing in T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for a variety of therapeutic and diagnostic applications. AIT is also focused on identification and validation of novel therapeutic targets.

Applied Immune Technologies (AIT) is a drug development company specializing in T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for a variety of therapeutic and diagnostic applications. AIT is also focused o...Show all

Company (Acquired)

Phone: +972-4-8122216

Fax:

Gutwirth Industrial Park
Technion City
Haifa, 32000
Israel

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Applied Immune Technologies $4M Jan 27, 2016

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Applied Immune Technologies Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Immunogens for treatment of neoplastic and infectious disease Dec 30, 2011 Mar 03, 2015 Patent
Immunogens for treatment of neoplastic and infectious disease Mar 03, 2003 Jan 03, 2012 Patent
Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens Mar 03, 2003 May 18, 2010 Patent